DE60326262D1 - Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden - Google Patents
Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werdenInfo
- Publication number
- DE60326262D1 DE60326262D1 DE60326262T DE60326262T DE60326262D1 DE 60326262 D1 DE60326262 D1 DE 60326262D1 DE 60326262 T DE60326262 T DE 60326262T DE 60326262 T DE60326262 T DE 60326262T DE 60326262 D1 DE60326262 D1 DE 60326262D1
- Authority
- DE
- Germany
- Prior art keywords
- prevention
- treatment
- andropause
- carnitines
- diseases caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 abstract 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000620A ITRM20020620A1 (it) | 2002-12-13 | 2002-12-13 | Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. |
| PCT/IT2003/000757 WO2004054567A1 (en) | 2002-12-13 | 2003-11-20 | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60326262D1 true DE60326262D1 (de) | 2009-04-02 |
Family
ID=32587900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60326262T Expired - Lifetime DE60326262D1 (de) | 2002-12-13 | 2003-11-20 | Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7956091B2 (enExample) |
| EP (1) | EP1569635B1 (enExample) |
| JP (1) | JP4767542B2 (enExample) |
| KR (1) | KR101039818B1 (enExample) |
| AT (1) | ATE422883T1 (enExample) |
| AU (1) | AU2003288739A1 (enExample) |
| CA (1) | CA2507429C (enExample) |
| CY (1) | CY1109051T1 (enExample) |
| DE (1) | DE60326262D1 (enExample) |
| DK (1) | DK1569635T3 (enExample) |
| ES (1) | ES2322455T3 (enExample) |
| IT (1) | ITRM20020620A1 (enExample) |
| MX (1) | MXPA05006072A (enExample) |
| PL (1) | PL211032B1 (enExample) |
| PT (1) | PT1569635E (enExample) |
| SI (1) | SI1569635T1 (enExample) |
| WO (1) | WO2004054567A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272812A1 (en) * | 2002-02-07 | 2005-12-08 | Pettegrew Jay W | Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans |
| US7407778B2 (en) | 2002-02-07 | 2008-08-05 | Pettegrew Jay W | Compounds, compositions and methods for treating neuropsychiatric disorders |
| US7700074B2 (en) | 2002-02-07 | 2010-04-20 | Pettegrew Jay W | Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
| EP1641806B1 (en) | 2003-05-29 | 2009-07-29 | Jay W. Pettegrew | Glycerophosphocholine and its derivatives for medical imaging of neuropsychiatric disorders |
| ITRM20040561A1 (it) * | 2004-11-11 | 2005-02-11 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile. |
| KR101460125B1 (ko) * | 2013-02-05 | 2014-11-11 | 주식회사 바이오그랜드 | 루이보스 추출물을 유효성분으로 하는 남성 노화 및 갱년기 예방 및 개선용 조성물 |
| WO2016167254A1 (ja) * | 2015-04-17 | 2016-10-20 | 株式会社山田養蜂場本社 | 蜂の子を含有する滋養強壮剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3830931A (en) * | 1972-11-06 | 1974-08-20 | Felice S De | Carnitine and its use in the treatment of arrhythmia and impaired cardiac function |
| IT1206954B (it) * | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche |
| IT1116037B (it) * | 1979-04-23 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico |
| IT1157238B (it) * | 1982-10-29 | 1987-02-11 | Sigma Tau Ind Farmaceuti | Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile |
| EP0681839A3 (en) | 1994-05-12 | 1997-11-12 | Hirohiko Kuratsune | A pharmaceutical preparation comprising an acylcarnitine |
| IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
| IT1291127B1 (it) * | 1997-04-01 | 1998-12-29 | Sigma Tau Ind Farmaceuti | Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica |
| IT1295408B1 (it) * | 1997-10-03 | 1999-05-12 | Sigma Tau Ind Farmaceuti | Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo |
| IT1302125B1 (it) * | 1998-08-03 | 2000-07-31 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide |
| IT1302307B1 (it) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
| IT1306130B1 (it) * | 1999-04-16 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti. |
| US6399116B1 (en) * | 2000-04-28 | 2002-06-04 | Rulin Xiu | Rhodiola and used thereof |
| DE60216090T2 (de) * | 2001-05-29 | 2007-05-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia |
-
2002
- 2002-12-13 IT IT000620A patent/ITRM20020620A1/it unknown
-
2003
- 2003-11-20 WO PCT/IT2003/000757 patent/WO2004054567A1/en not_active Ceased
- 2003-11-20 AU AU2003288739A patent/AU2003288739A1/en not_active Abandoned
- 2003-11-20 US US10/535,509 patent/US7956091B2/en not_active Expired - Lifetime
- 2003-11-20 SI SI200331543T patent/SI1569635T1/sl unknown
- 2003-11-20 EP EP03780642A patent/EP1569635B1/en not_active Expired - Lifetime
- 2003-11-20 ES ES03780642T patent/ES2322455T3/es not_active Expired - Lifetime
- 2003-11-20 DK DK03780642T patent/DK1569635T3/da active
- 2003-11-20 KR KR1020057009768A patent/KR101039818B1/ko not_active Expired - Fee Related
- 2003-11-20 AT AT03780642T patent/ATE422883T1/de active
- 2003-11-20 DE DE60326262T patent/DE60326262D1/de not_active Expired - Lifetime
- 2003-11-20 MX MXPA05006072A patent/MXPA05006072A/es active IP Right Grant
- 2003-11-20 JP JP2004560181A patent/JP4767542B2/ja not_active Expired - Fee Related
- 2003-11-20 PL PL378418A patent/PL211032B1/pl unknown
- 2003-11-20 PT PT03780642T patent/PT1569635E/pt unknown
- 2003-11-20 CA CA2507429A patent/CA2507429C/en not_active Expired - Lifetime
-
2009
- 2009-05-07 CY CY20091100492T patent/CY1109051T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1569635E (pt) | 2009-05-11 |
| JP2006511531A (ja) | 2006-04-06 |
| MXPA05006072A (es) | 2005-09-30 |
| US20060135606A1 (en) | 2006-06-22 |
| CA2507429C (en) | 2012-09-04 |
| KR20050084052A (ko) | 2005-08-26 |
| ITRM20020620A1 (it) | 2004-06-14 |
| ES2322455T3 (es) | 2009-06-22 |
| DK1569635T3 (da) | 2009-04-20 |
| CA2507429A1 (en) | 2004-07-01 |
| EP1569635A1 (en) | 2005-09-07 |
| EP1569635B1 (en) | 2009-02-18 |
| ATE422883T1 (de) | 2009-03-15 |
| AU2003288739A1 (en) | 2004-07-09 |
| SI1569635T1 (sl) | 2009-06-30 |
| WO2004054567A1 (en) | 2004-07-01 |
| PL211032B1 (pl) | 2012-04-30 |
| US7956091B2 (en) | 2011-06-07 |
| JP4767542B2 (ja) | 2011-09-07 |
| PL378418A1 (pl) | 2006-04-03 |
| KR101039818B1 (ko) | 2011-06-09 |
| CY1109051T1 (el) | 2014-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2341973A1 (en) | Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid | |
| FI3457135T3 (fi) | Fabryn taudin hoitovaihtoehtoja | |
| NO20050896L (no) | Probiotika for neuromuskulaere funksjoner i tarmen | |
| CY1109051T1 (el) | Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση | |
| BRPI0410131A (pt) | suplemento dietético para uso no tratamento e/ou inibição de úlceras do trato digestivo em equinos e outros animais e seu método | |
| IT1295408B1 (it) | Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo | |
| AR021172A1 (es) | Composicion antiprolifica, antioxidante, que comprende una carnitina y un carotenoide | |
| WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases | |
| EP1806983B8 (en) | Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal | |
| ATE445394T1 (de) | Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienz | |
| SG162836A1 (en) | Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases | |
| SI1492521T1 (sl) | Kombinirana uporaba l-karnitina, acetil l-karnitina in propil l-karnitina za zdravljenje oligoastenoteratospermije | |
| ATE259778T1 (de) | Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten | |
| DE69428797D1 (de) | Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden | |
| PL1824472T3 (pl) | Zastosowanie acetylo-L-karnityny do wytwarzania leku do leczenia zespołu fibromialgii | |
| RU2002121267A (ru) | Способ профилактики и лечения язв желудка у животных | |
| DE60222662D1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung | |
| UY27475A1 (es) | Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización | |
| PT1937245E (pt) | Composto útil para a prevenção e o tratamento de hipertrofia ventricular esquerda em pacientes dialisados | |
| RU2002102279A (ru) | Комплексный способ химиолучевой- и диетотерапии при лечении онкологических заболеваний | |
| RU2002132905A (ru) | Способ лечения атопического хейлита у детей | |
| CN1223128A (zh) | 降压减肥茶 | |
| RU2002123989A (ru) | Способ лечения хронических заболеваний печени с проявлениями нарушений микроэкологии кишечника | |
| RU2002127274A (ru) | Применение препарата ветом-7048 впервые в качестве лекарственного препарата при лечении атрофии мозга, гидроцефалии мозга | |
| RU2002109171A (ru) | Способ лечения сердечно-сосудистых заболеваний у больных с эрозивно-язвенными поражениями эзофагогастродуоденальной зоны |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |